#NSCLC

Nathan A. Pennell MD, PhD, FASCO

n8pennell

THREAD: I have heard a lot of self-righteous indignation about how we would be bankrupting the system with adjuvant targeted treatment for EGFR mutation+ NSCLC pts, so let's take a

Nathan A. Pennell MD, PhD, FASCO

n8pennell

I messed up my poster so attaching slides here (Abstract 9529: A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with

Stephen V Liu

StephenVLiu

#ESMO20 Much anticipated results from CodeBreaK100: AMG 510 (sotorasib) in #KRAS G12C #NSCLC by @DavidHongMD building on exciting data seen over the past two years for this huge unmet need.

Ryan Reeves

investing_city

Genomics Thread #6Let's talk about liquid biopsies... 1/ A liquid biopsy is usually a blood-based test that can detect cancer. How?By detecting either CTC (circulating tumor cells) or ctDNA (circulating

Santiago Viteri

DrViteri

I am honored to be part of this piece of the lung cancer story. Tepotinib in NSCLC with MET exon 14 skipping mutations. #NSCLC #METex14 #Tepotinib #LCSM https://www.nejm.org/doi/full/10.1056/NEJMoa2004407?source=nejmtwitter&medium=organ

Natasha Rekhtman MD PhD

natasharekhtman

Hi pathology friends! Lung pathology is on everyone’s minds these days… but lets talk about a different type of #pulmpath issue. Lung mass in a 60-yo patients. Core bx. What

Kartik Sehgal

KartikSehgal_MD

Delay/extension of pembro-based Rx for advanced NSCLC expected #COVID19. In preprint @medRxiv, our experience with outcomes in patients who received atleast ≥4 cycles and had delays/extensions. Results hypothesis-generating only but

Clive Peedell

cpeedell

Can we achieve similar outcomes for lung #SABR in non-academic institutions compared to the major academic centres? This was an important question posed by @drdavidpalma Suresh Senan & @FJLagerwaard. This

bio(il)logical capital

bioILLOGICAL

$BYSI interesting here. Plinabulin +++ Ph3 data in CIN. Used on top of SoC G-CSF. Chemo is still broadly used (despite I/O and targeted therapies) and Gr4 neutropenia still occurs

Peter B. Bach, MD

peterbachmd

Intriguing @theNCI @NCIDrDougLowy @NEJM study showing lung cancer mortality rates falling since 2013 faster than incidence rates. Study title claims they observed the impact of improved treatments. I think that

Kevin Stephans MD

MdStephans

(1/5) The COVID era is aperfect time to adopt single fraction lung SBRT. This is supported by tworandomized trials suggesting comparable outcome for 30-34 Gy in 1 fraction formedically inoperable

Stag

thestaghound

Did some work on $VSTM, and just wanted to share some high level thoughts and questions from my thesis (I'm long $VSTM, spoiler alert) but have a fair amount of

Mike Pishvaian

MPishvaian

1/@OncoAlert #ASCO2020 In addition to the outstanding GI abstracts, there will be many presentations and posters adding to the wealth of data that demonstrate that a real percentage of almost

David Sampson

djsampson

Time to dive into #ASCO20 abstracts! High vegetable protein intake associated w/lower risk of breast cancer incidence & post dx death; higher animal protein intake associated w/higher risk of br

Amit Kulkarni

AmitKulkarniMD

#FDA recently approved #pembrolizumab- a tissue agnostic indication in metastatic tumors with high #TMB (>10 mut/MB) using Foundation One Dx companion diagnostic test. I want to share a tweetorial on

Patrick Forde

FordePatrick

Today at #AACR21 I was honored to present results of the phase 3 CheckMate 816 neoadjuvant chemo-nivo lung cancer trial on behalf of all the colleagues, patients & families who